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MINIREVIEW
It’s Not Easy Being Green: the Viridans Group Streptococci, with a
Focus on Pediatric Clinical Manifestations
Christopher D. Doern1* and Carey-Ann D. Burnham2
Department of Pathology, University of Texas Southwestern, Dallas, Texas 75235,1 and Departments of Pediatrics and
Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri 631102
The viridans group streptococci (VGS) are a heterogeneous group of organisms that can be human com-
mensals, colonizing the gastrointestinal and genitourinary tracts in addition to the oral mucosa. VGS are
generally considered to be of low pathogenic potential in immunocompetent individuals. However, in certain
patient populations, VGS can cause invasive disease, such as endocarditis, intra-abdominal infection, and
shock. Within the VGS, the rates and patterns of antimicrobial resistance vary greatly depending upon the
species identification and the patient population. In general, Streptococcus mitis group organisms are resistant
to more antimicrobial agents than the other VGS species. This review addresses current VGS taxonomy, in
addition to the current methodologies being used in clinical microbiology laboratories for identification of
VGS. Automated systems struggle overall with species level identification and susceptibility testing for VGS.
Matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) identification is emerging as a
potential alternative for organism identification. A review of recent pediatric-specific data regarding the
clinical manifestations of VGS revealed that the Streptococcus anginosus group (SAG) organisms may be
important pathogens in pediatric patients and that the VGS may contribute to disease in patients with cystic
fibrosis. It also appears that rates of antimicrobial resistance in VGS in pediatric patients are surpassing those
of the adult population.
TAXONOMY AND MICROBIOLOGY
The viridans group streptococci (VGS) are a heterogeneous
group of organisms that can be both commensal flora and
pathogens in humans. They are the “grab bag” that remains
when the beta-hemolytic streptococci, enterococci, and pneu-
mococci are excluded from the streptococci. The purpose of
this review is to summarize the currently accepted taxonomic
classification of this group of organisms, examine the state of
the art for identification of the VGS, and then focus on the
pediatric clinical manifestations associated with the VGS.
Perhaps the only consistency observed in discussions regard-
ing the taxonomy of the VGS is a lack of consistency. The
taxonomy is very controversial, and for many years, a standard-
ized naming scheme or typing system for this group of organ-
isms was lacking; therefore, discussions on this topic frequently
include the phrase “poorly classified.” There are now at least
30 recognized species of VGS (11, 14).
One of the first classifications of VGS was done in 1906 by
Andrewes and Horder, who classified three species of nonhe-
molytic Streptococcus as the “Streptococcus mitis group” (14).
This group has been poorly defined for many years because of
the paucity of commonly queried substrates hydrolyzed by the
group. So began the taxonomic problems with this group of
organisms. Today, the VGS are classified into 6 major groups:
the S. mutans group, S. salivarius group, S. anginosus group, S.
mitis group, S. sanguinis group, and S. bovis group (14).
The S. anginosus group is one that has been the source of
much controversy and confusion regarding taxonomy and clas-
sification. This group of organisms can be alpha-, beta- or
nonhemolytic; it is the isolates lacking beta-hemolysis that are
generally lumped into the VGS. The group includes S. angi-
nosus, S. constellatus, and S. intermedius. However, each of
these species has been known as S. anginosus or S. milleri at
one time (11, 14). S. milleri has never been accepted as a
confirmed taxonomic entity, although historically, it has been
widely used interchangeably with the S. anginosus group.
IDENTIFICATION
Phenotypic and biochemical identification. Identification of
VGS to the species level can be difficult, and phenotypic iden-
tification is not always accurate. The name “viridans” is some-
what of a misnomer, as many species do not produce any
hemolysis on blood agar. From a classification perspective, it is
not useful to try to differentiate alpha-hemolysis from a lack of
hemolysis on blood agar plates (sometimes referred to as
“gamma-hemolysis”); this feature can vary widely with the
growth medium used to cultivate the organism, as well as the
incubation temperature. Lack of alpha hemolysis does not
seem to correlate with the clinical outcome or severity of dis-
ease; no enzymatic or toxigenic effect has ever been docu-
mented as a by-product of alpha hemolysis.
The VGS are a group of catalase-negative, Gram-positive
cocci with a chaining morphology on microscopic examination.
They are leucine aminopeptidase positive, pyrrolidonylaryl-
* Corresponding author. Mailing address: 1935 Medical District
Drive, Mail code B1.06, Dallas, TX 75235. Phone: (214) 456-1344. Fax:
(214) 456-4713. E-mail: christopher.doern@utsouthwestern.edu.
 Published ahead of print on 1 September 2010.
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amidase negative, and do not grow in 6.5% NaCl, and almost
all species are negative for growth on bile esculin agar. They
differ from pneumococci in that they are optochin resistant and
are not bile soluble. However, Richter et al. examined mis-
identification of VGS submitted to antimicrobial surveillance
programs as pneumococci and found that the distinction of S.
pneumoniae from the VGS can be difficult, which is not sur-
prising in light of the fact that S. mitis and S. oralis possess
99% sequence homology with S. pneumoniae (47). The au-
thors also found that optochin disk testing did not perform as
well as bile solubility testing for identification; in a survey of
1,733 isolates tested, bile solubility testing had higher sensitiv-
ity and specificity for differentiation of VGS from pneumococci
(47).
S. anginosus group. The S. anginosus group of organisms can
be beta-, alpha- or nonhemolytic. The isolates lacking beta-
hemolysis are generally those grouped with the VGS. S. con-
stellatus is the most likely of this group to be beta-hemolytic.
There is some evidence implicating beta-hemolytic S. constel-
latus subsp. pharyngis as a cause of pharyngitis (55). S. inter-
medius is the species in this group most commonly isolated
from brain and liver abscesses. The S. anginosus group can
possess Lancefield group antigens A, C, G, and F, although S.
intermedius almost never possesses Lancefield group antigens.
Isolates of the S. anginosus group have a characteristic “but-
terscotch” odor. Members of the group are universally positive
for three biochemical reactions: acetoin production from glu-
cose (positive Vogues-Proskauer reaction), arginine, and sor-
bitol. These are very useful for the differentiation of this group
from other VGS.
S. mitis group. The S. mitis group of organisms contains
several species and is biochemically very inert, which can make
species level identification very challenging. The use of invalid
species names has also been a particular problem with the S.
mitis group. Isolates in this group are negative for acetoin
production, arginine, esculin, and mannitol and are sorbitol
fermentation negative (14). S. pneumoniae is a recently char-
acterized member of the S. mitis group (1). As the organism is
closely related to S. pneumoniae and other S. mitis group or-
ganisms, accurate identification can be difficult. S. pseudopneu-
moniae lacks the pneumococcal capsule and is resistant to
optochin when incubated in an atmosphere with elevated CO2
but is susceptible when incubated in ambient air. Bile solubility
is a more specific test for S. pseudopneumoniae than optochin
susceptibility, as the organism is not bile soluble (1).
S. sanguinis group. The genetically heterogeneous S. sangui-
nis group was formerly known as S. sanguinis. Some taxono-
mists have lumped the S. sanguinis group in with the S. mitis
group based on 16S rRNA gene sequence analysis, but S.
sanguinis group organisms exhibit divergent phenotypic char-
acteristics. Isolates in the S. sanguinis group are arginine and
esculin positive. Like members of the S. mitis group, they are
negative for acetoin production and mannitol and sorbitol fer-
mentation. The S. sanguinis group includes S. sanguinis, S.
parasanguinis, and S. gordonii (14).
S. bovis group. The S. bovis group includes S. equinus, S.
gallolyticus, S. infantarius, and other closely related species;
they are the nonenterococcal group D streptococci. Members
of this group are esculin positive and sorbitol negative and
produce acetoin. Historically, S. bovis had been divided into
three biotypes: I (mannitol fermentation positive), II/1 (man-
nitol negative and beta-glucuronidase negative), and II/2
(mannitol negative and beta-glucuronidase positive) (14). Fur-
ther characterization demonstrated that biotype II/1 was S.
infantarius subsp. coli and II/2 was S. gallolyticus subsp. paste-
ruianus. Isolates from the S. bovis group are most frequently
encountered in blood cultures from patients with colon cancer.
However, S. bovis group organisms (especially S. gallolyticus
subsp. gallolyticus and S. infantarius subsp. coli) have been
associated with endocarditis (3). Although infection with S.
bovis group organisms occurs with higher frequency in adults
than in pediatric patients, these organisms have been reported
to cause neonatal sepsis and meningitis (20).
S. salivarius group. The S. salivarius group is closely related
to the S. bovis group. Species from this group that have been
isolated from human infection include S. salivarius and S. ves-
tibularis, as well as S. thermophilus, which has been identified
from dairy products. S. salivarius group organisms are positive
for acetoin production and are esculin positive but are negative
for arginine hydrolysis and fermentation of mannitol and sor-
bitol.
S. mutans group. Members of the S. mutans group are pri-
marily isolated from the human oral cavity and includes several
species that are phenotypically similar. S. mutans and S. sob-
rinus are the species within this group most commonly isolated
from human infection. They do not hydrolyze arginine but are
positive for acetoin production, esculin hydrolysis, and manni-
tol and sorbitol fermentation.
Automated biochemical methods for identification. For the
VGS, the use of automated systems for identification has his-
torically been reported as problematic, and this theme applies
to multiple automated methodologies. One of the major fac-
tors affecting the quality of the identifications generated is
that the systems may not have all species represented in their
databases (32). In one investigation comparing the accuracy of
the Vitek2 ID-GPC card to that of conventional agar-based
biochemical methods for identification of a variety of Gram-
positive and Gram-negative organisms, 72% of Gram-positive
isolates were accurately identified by the Vitek2 system (21).
Among the most problematic identifications (whether incor-
rectly identified or unresolved) were the VGS; S. anginosus, S.
mutans, and S. sanguinis were misidentified as other VGS spe-
cies and, in some instances, as S. pneumoniae (21).
An investigation into the ability of the BD Phoenix system
SMIC/ID panel to identify Streptococcus spp. classified 97 con-
secutive clinical isolates of streptococci, including 34 isolates of
VGS, with biochemical methods as the reference method (26).
Ninety-one percent of the streptococcal isolates showed agree-
ment between the Phoenix and the reference method. Of the
12 S. mitis group isolates tested, the Phoenix system correctly
identified 7 isolates, with 2 discordant identifications, and there
were 3 isolates for which the Phoenix system did not produce
any identification. Of 22 S. anginosus group isolates, 18 were
correctly identified and 4 were discordant. A second study
evaluated the Phoenix SMIC/ID-2 panel using the API 20
Strep system as a comparator method (resolving discrepant
results via 16S rRNA gene sequencing and amplification and
sequencing of housekeeping genes) (5). For the VGS, 31 iso-
lates were assayed, with only 53% concordance between the
Phoenix and reference methods for S. mitis group organisms,
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100% concordance for the S. anginosus group, and 75% con-
cordance for S. sanguinis group organisms (5).
Sequence-based identification. Historically, DNA-DNA hy-
bridization studies have been used to confirm species level
identifications for the VGS. However, these procedures are
not practical for clinical laboratories to use for identification of
these organisms. Other sequence-based identification systems
have subsequently been introduced for VGS species level iden-
tification. In general, 16S rRNA gene sequencing results in
poor resolution to species level in the VGS. This is due to the
high degree of 16S rRNA gene homology in this group of
organisms; S. mitis, S. oralis, S. pseudopneumoniae, and S.
pneumoniae almost always have 99% sequence homology in
this gene. In light of the high degree of 16S rRNA gene se-
quence similarity, sequencing of alternative gene targets for
reliable identification to the species level has been explored.
One promising target, rnpB, was explored by Innings et al., who
analyzed 2 variable regions of rnpB by pyrosequencing (28). Of
the 43 species analyzed, all were identified to species level,
except for 2 isolates: S. anginosus/S. constellatus and S. infan-
tis/S. peroris. rnpB can be used for identification of VGS with
high-level resolution. One other successful approach is se-
quence analysis of the manganese-dependent superoxide dis-
mutase gene, described by Poyart et al. This technique was
used to accurately differentiate over 29 streptococcal species,
including 16 VGS species, with clear differentiation of S. mitis,
S. oralis, and S. pneumoniae (44, 45). Other techniques that
have been used, with various degrees of success, are sequence
analysis of the 16S-23S intergenic spacer region, D-alanine-D-
alanine ligase gene sequencing, and hyaluronate lyase gene
sequencing.
EMERGING TECHNOLOGIES
MALDI-TOF. Matrix-associated laser desorption ioniza-
tion–time of flight (MALDI-TOF) is gaining momentum as a
rapid and cost-effective means of identification of pure cultures
of bacteria, as well as direct identification of microorganisms
from positive blood culture broth. In 2007, Friedrichs and
colleagues assessed the utility of MALDI-TOF for identifying
VGS from relevant clinical samples, following a preliminary
identification based on phenotypic analysis (17). MALDI-TOF
identification was compared to biochemical analysis using the
RAPID Strep assay, and discrepant results were resolved using
16S rRNA gene sequencing and organism-specific PCR assays.
A series of reference strains was used to produce a spectrum
database with the Bruker Daltonics MALDI-TOF platform.
Ninety-nine clinical isolates (isolated from blood cultures, peri-
tonsillar abscesses, other abscesses, wounds, catheter tips, and
cerebrospinal fluid [CSF]) were analyzed, and 10 different
VGS species were included in the analysis, although the ma-
jority of them were S. mitis group and S. anginosus group
members. The analysis revealed that the spectra of more
closely related organisms (such as those within the S. anginosus
group) were more similar than those that were more antigeni-
cally distinct (such as S. salivarius and S. mutans). Twenty-three
samples were identified as S. mitis or S. oralis by species-
specific PCR and 16S rRNA gene sequence analysis; in all but
two cases, these were identified correctly by MALDI-TOF
(17). In general, MALDI-TOF appeared to be a rapid and
accurate mode of VGS identification.
Studies are also emerging that examine the ability of
MALDI-TOF to identify VGS directly from positive blood
culture broth. Overall, the preliminary results are promising,
but MALDI-TOF may suffer from the same limitation as 16S
rRNA gene sequence-based identification—poor resolution of
S. mitis group organisms and S. pneumoniae to the species level
(9, 16).
ANTIMICROBIAL SUSCEPTIBILITIES OF VIRIDANS
GROUP STREPTOCOCCI
Automated systems. Just as automated systems struggle with
accurate identification of VGS, they may be less than ideal at
performing accurate susceptibility testing for these organisms.
A 2007 study by Richter et al. queried the ability of the BD
Phoenix system to accurately provide antimicrobial suscepti-
bility results for 2,013 streptococcal isolates tested against 13
antimicrobial agents (48). Broth microdilution was used as the
reference method. For the 369 VGS isolates, the minor error
rate was 10% for some of the antimicrobial agents tested.
The very major error rate was up to 3%, and very major errors
occurred with 7 of the antimicrobial agents. Categorical agree-
ment was below 90% for penicillin. The VGS had the lowest
rate of concordance between the Phoenix and the reference
method of all the streptococci queried in the study. However,
the average time to results was approximately 9 h, making
automated testing a very enticing option. A second, smaller
study (32 VGS isolates) evaluating the Phoenix SMIC-ID2
panel (compared to Etest as a reference method) was more
favorable, with no major, minor, or very major errors observed
with the 8 antimicrobial agents tested (6).
Epidemiology of resistance in children. In 1949, a published
series describing 57 cases of subacute endocarditis identified a
single fatality due to a highly penicillin-resistant VGS (24).
Sixty years later, penicillin is still an important antibiotic in
treating VGS infections, and resistance continues to increase
in the face of its use. A recent survey of Gram-positive cocci
isolated in North America showed that of 182 VGS, 28.6%
were nonsusceptible to penicillin, with only 4.9% being fully
resistant (8). These findings are consistent with those of others
in Europe and Asia. The profile for clindamycin is somewhat
similar in that 6.6% of isolates were resistant; however there
were no intermediately resistant isolates, as 93.4% were sus-
ceptible. VGS in this study were most resistant to the macro-
lide erythromycin, with nearly 50% being fully resistant. This
study provides a nice overview of the VGS resistance picture,
but the epidemiology is too complex to be summarized as a
group. VGS resistance rates vary widely between species and
even within different patient populations. Some have even
shown that resistance appears to be more prevalent in the
pediatric versus adult population (25, 39).
In pediatric and adult populations alike, those most at risk
for resistant VGS infections are the immunocompromised.
Not coincidentally, this is also a population that receives
frequent antibiotic treatment. The mantra that antibiotic
usage drives resistance holds true for VGS, and there are
numerous studies that have shown direct correlations be-
VOL. 48, 2010 MINIREVIEW 3831
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tween both penicillin and macrolide usage and the develop-
ment of resistance in VGS.
In 2001, Kastner and Guggenbichler conducted a random-
ized controlled study in which the development of macrolide
resistance was assessed in children being treated for upper
respiratory tract infections (31). Patients were excluded from
the study if any macrolide-resistant organisms were found in
initial pretreatment cultures. After only 1 week of treatment,
over 60% of the patients in both the azithromycin and clarith-
romycin groups had at least one macrolide-resistant organism;
6 weeks following antibiotic treatment, 87% of the patients in
the azithromycin group were colonized with macrolide-resis-
tant VGS. Clarithromycin-treated patients fared slightly better
at 6 weeks posttreatment, but 60% still had macrolide-resistant
VGS colonizing their oral mucosa.
Malhotra-Kumar et al. showed similar trends in their 2007
study in healthy nonpediatric volunteers. Their study demon-
strated an effect on colonizing resistant VGS 6 months post-
therapy (35). As in the Kastner and Guggenbichler study, they
found that azithromycin was more likely than clarithromycin to
select for macrolide resistance initially and to maintain that
resistance over extended periods of time. They also showed
that azithromycin was more likely to select for resistance than
clarithromycin. Both azithromycin and clarithromycin select
for VGS possessing the ermB gene, which can be carried on the
same mobile genetic element as the tetracycline resistance
gene, tet(M). This has obvious implications for the selection of
multiclass resistance. The Castanheira et al. data may support
this hypothesis, as macrolide resistance rates in their study
were similar to those for tetracycline (8). With respect to
penicillin, the story is the same. Studies have shown that VGS
penicillin resistance rates are significantly higher in those pa-
tients receiving penicillin than in those who are not (23).
One patient population at particular risk for developing
resistant VGS infection is pediatric oncology patients. Recent
analyses of VGS bacteremia isolates in this population have
shown anywhere from 21 to 37% to be resistant to penicillin.
Penicillin resistance is often accompanied by resistance to
other beta-lactams, such as ceftriaxone and cefepime, as well as
other classes of antibiotics (7).
Another population at risk of harboring drug-resistant VGS
is the cystic fibrosis (CF) population. Evidence, discussed be-
low, is starting to suggest that S. anginosus group organisms
may be important pathogens in this population whereas other
VGS colonize the cystic fibrosis lung in a nonpathogenic ca-
pacity. These patients receive many antibiotics which likely
have poor penetration into the lung and provide an ideal en-
vironment for the development of resistance. To compound
the matter, CF patients are commonly treated with azithromy-
cin for its anti-inflammatory effect and with the hope that it will
interrupt quorum-sensing mechanisms employed by Pseudo-
monas aeruginosa. Altogether, the CF patient is at very high
risk for colonization with drug-resistant VGS. In one study
where macrolide resistance was measured for VGS isolated
from respiratory cultures of CF patients, 95% of VGS were
macrolide nonsusceptible and 80% were fully resistant (52).
Among viridans group streptococci, S. mitis group organisms
are the most likely to become resistant to beta lactam and
macrolide antibiotics. Within one study, 56% of S. mitis iso-
lates were resistant to 3 classes of antibiotics (39). This is in
contrast to the S. anginosus, S. sanguinis, S. salivarius, and S.
bovis groups, which remain relatively susceptible to penicillin
(49). Of the non-S. mitis VGS in this study, only 9% of S.
salivarius strains demonstrated high penicillin resistance. No
resistance was observed in the other non-S. mitis VGS. The
implications of S. mitis resistance go beyond infection with S.
mitis itself. As was discussed above, the S. mitis/S. oralis species
are closely related to S. pneumoniae, and through recombina-
torial events, they are thought to have played a crucial role in
the development of pneumococcal resistance.
Although VGS resistance to penicillin and the macrolide-
lincosamide-streptogramin B (MLS) drugs is an evolving prob-
lem, several drugs remain uniformly active against the VGS.
Thus far, VGS resistance to vancomycin, linezolid, and dapto-
mycin remains extremely rare (8).
CLINICAL SIGNIFICANCE
VGS are considered to be normal flora of the oropharyn-
geal, urogenital, and gastrointestinal microbiota. They are not
typically thought of as organisms with high pathogenic poten-
tial; however, VGS infection can be associated with significant
morbidity and mortality. Although VGS disease can occur in
healthy hosts, it most commonly manifests in those with un-
derlying conditions, such as being immunocompromised or
having cardiac abnormalities. Below, we review the specific
manifestations of pediatric VGS disease, focusing on recent
publications and highlighting new disease associations.
Infective endocarditis. Infective endocarditis (IE) occurs
less frequently in children than it does in adults, at a rate of 1
per 1,280 pediatric admissions. In a 2004 retrospective review
of 2,071 pediatric cardiology consultations, only 4.4% were for
suspicion of subacute endocarditis. Of that 4.4%, in only 3
cases (3.3%) was a culture-confirmed diagnosis of infective
endocarditis made. Two of the three episodes were due to
VGS; the third was due to Staphylococcus aureus (22). Al-
though pediatric infective endocarditis is rare, when it does
occur, a significant percentage of episodes are due to viridans
group streptococci. Ferrieri et al. conducted a review of the
literature and found that VGS was the most common cause of
IE in children. The studies reviewed found VGS to be the
cause of between 32 and 43% of cases (15, 30, 36, 51). In
addition, 27 to 33% of IE was caused by S. aureus, which was
the second most common etiologic agent. 2000 and 2003 data
presented by Day et al. suggest a slightly different epidemiol-
ogy, with VGS and S. aureus causing 20 and 57% of cases,
respectively (12). Overall, Day et al. found the mortality of IE
in children to be relatively low at 5.3%. Of the 14 noninfant
children who died from IE, S. aureus was the causative agent in
93% of the cases. They also concluded that VGS are particu-
larly important causes of IE after the first year of life and are
more frequently associated with native valve endocarditis.
VGS IE is more likely to occur more than 60 days after surgery,
consistent with the subacute nature of VGS IE (15). Most
commonly, VGS endocarditis presents with an indolent course
involving prolonged low-grade fever and a variety of somatic
complaints, such as arthralgias, myalgias, weight loss, rigors,
fatigue, weakness, and diaphoresis. As in adults, it is very
common for these children to have continuous bacteremia.
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S. anginosus group. Members of the S. anginosus group of
organisms are well recognized for their predilection for abscess
formation. In contrast to other species of VGS, where disease
typically occurs in hosts with underlying conditions, SAG or-
ganisms commonly cause disease in healthy hosts. In a 2002
retrospective analysis of pediatric S. anginosus group infection,
Belko et al. found that only 18% of patients had a risk factor
for infection (4). Of those with risk factors, congenital abnor-
mality was the most common. In the 180 patients who devel-
oped S. anginosus disease, only 12 (7%) had a congenital ab-
normality while 146 (82%) had no identifiable risk factor.
Although the specific disease manifestation was not stated in
the study, the most common abnormalities were cyanotic heart
disease (n  4) and myelomeningocele (n  2). As is true in
the adult population, the abdomen was the primary site of
infection, followed by superficial skin infections. Over the
6-year period of the Belko study, 29% of all central nervous
system (CNS) cultures that were positive for a bacterial agent
were positive for an S. anginosus group organism. Interestingly,
in this study of 213 SAG isolates, no S. anginosus sensu stricto
isolates were identified. However, 40% of the SAG organisms
were identified only as group F streptococci and could have
been S. anginosus. At least one other study has found a similar
result in children, where 14 of 16 isolates that were identified
to the species level were S. intermedius and no S. anginosus
isolates were identified (29). This is in contrast to data pre-
sented by others who have found S. anginosus to be the pre-
dominant disease-causing SAG organism. However, the pa-
tient populations in these studies were not defined as pediatric
(2, 10, 53, 54). It is possible that S. intermedius plays a more
significant role in pediatric infection than does S. anginosus,
but more data are needed to make a firm association. Several
studies have suggested a correlation between SAG species and
the site of infection. Although not all the studies were con-
ducted in pediatric populations, S. intermedius seems to have a
predilection for the CNS, while S. constellatus may be more
often involved in pulmonary infection (53). Overall, the mor-
tality for SAG pediatric infections is low. Of the 213 SAG
organisms isolated in the Belko study, there was no mortality.
This included 11 episodes of CNS disease.
An emerging body of evidence suggests that SAG is a sig-
nificant pathogen in patients with CF, but thus far, few studies
have been conducted in the pediatric CF population. Parkins
et al. published a series of 10 cases of SAG disease in adults
with CF. In 7 of the 10 cases, bronchopulmonary symptoms
were attributed to SAG, as they were the predominant organ-
ism and patients responded both clinically and bacteriologi-
cally to SAG-specific treatment (43). Whether SAG is the sole
cause of disease in these patients remains to be seen. Parkins
and others have found that SAG disease in CF patients is
almost always associated with P. aeruginosa cocolonization
(50). This is not surprising, as a high percentage of CF patients
are colonized with P. aeruginosa by early adulthood. However,
there is evidence that P. aeruginosa and SAG may work syn-
ergistically to cause disease (13). In most published cases of
SAG disease, patients responded to SAG-specific therapy that
would not have had activity against P. aeruginosa. This suggests
that at the very least SAG is a critical component of disease in
these cases. More studies in the CF population will be needed
to determine whether SAG is the sole cause of disease or is
working in conjunction with P. aeruginosa.
Viridans group streptococci in pediatric cancer patients.
The VGS are common causes of bacteremia in pediatric cancer
patients, specifically those that are febrile and neutropenic. In
the late 1980s, an increase in VGS bacteremia in this patient
population was thought to be due to an increase in central
venous catheter use. Since that time, anywhere from 11 to 30%
of blood cultures from febrile, neutropenic cancer or stem cell
transplant patients have been positive for VGS in various se-
ries. In a 4-year retrospective study, Husain et al. found 33
episodes of bacteremia in this patient population. Of these,
58% were due to S. mitis and 21% were due to S. oralis (27).
The predominance of S. mitis bacteremia may be explained by
studies showing that in children undergoing allogeneic bone
marrow transplants, the overall bacterial flora decreases but S.
mitis becomes the dominant VGS species (34). Although nu-
merous risk factors have been identified for VGS bacteremia,
the last finding is consistent with others that suggest that re-
ducing competing flora increases the risk of becoming bacte-
remic with a VGS. Through selective pressure, antibiotics that
target Gram-negative organisms, such as quinolones, may pro-
mote VGS expansion and increase the risk of a patient becom-
ing bacteremic (41, 46). Although quinolones are generally
avoided in pediatrics, they may present an appealing oral op-
tion for prophylaxis of febrile and neutropenic pediatric cancer
patients (41). Mucositis is another important risk factor for
VGS bacteremia, specifically S. mitis bacteremia. Of those
patients who had mucositis-associated bacteremia, 66% was
due to S. mitis. Not only is S. mitis the most frequent VGS
species causing bacteremia, it is also the most likely to be
penicillin resistant. Despite the relatively high rate of penicillin
resistance in S. mitis, there was no association between resis-
tance and the risk for developing complications. However,
resistance was correlated with fever lasting more than 10 days
(27). Other studies have found that there is in fact a correlation
between increased resistance and mortality (40).
Mucositis is the most common route of entry for these or-
ganisms; however, in the Hussain study, nearly half the cases of
bacteremia (45%) occurred in patients without mucositis, sug-
gesting that other mechanisms of entry are also important. In
those that become bacteremic in the absence of mucositis,
gastrointestinal toxicity was implicated as a potential risk fac-
tor (18). S. acidominimus was implicated in 12% of the cases.
This species is part of the normal flora of the vagina, and all
cases occurred in female patients, suggesting genitourinary
entry. Other important risk factors for developing VGS bacte-
remia are treatment with high dose 1--D-arabinofuranosylcy-
tosine (ara-C) (HiDAC) and severe neutropenia (500 cells/
mm3) (27).
VGS bacteremia often results in complications, the most
serious of which is viridans streptococcal shock syndrome
(VSSS), with published mortality rates in children ranging be-
tween 40 and 100% (19, 37). In contrast to adult cancer pa-
tients, the pediatric population may be particularly prone to
developing VGS bacteremia and subsequent VSSS. As many as
25% of children with VGS bacteremia may go on to develop
VSSS. S. mitis is the most common VGS species associated
with VSSS. Attempts to identify the mechanism by which S.
mitis might cause sepsis have led to mixed results. Ohuoba et
VOL. 48, 2010 MINIREVIEW 3833
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al. published a 2006 report in which they failed to identify any
S. mitis superantigens that were either novel or homologous to
those of group A Streptococcus (42). This is in contrast to other
studies which have analyzed S. mitis supernatants and found
them to be capable of stimulating T-cell proliferation re-
sponses, suggesting the production of a superantigen (38). Lu
et al. later found that S. mitis produces a 34-kDa exoprotein
that may possess superantigen-like activity (33). Additional
studies are required to more clearly define the mechanism by
which VGS cause VSSS.
SUMMARY
In summary, the VGS are important pathogens in the pedi-
atric population. In fact, evidence suggests that children may
be at greater risk of VGS infection than adults. A new disease
association has been made for SAG organisms in CF patients.
However, more studies within the pediatric CF population are
needed to better understand the role of SAG disease in chil-
dren. The evolution of resistance marches on in VGS. Indis-
criminate use of azithromycin to treat respiratory illness and its
use as a prophylactic agent in the CF and oncology populations
are thought to exacerbate this problem. Penicillin resistance is
also a prominent problem in pediatric oncology patients, a
population at great risk of developing serious VGS infection.
Historically, VGS have been troublesome organisms to accu-
rately characterize and identify. Recently, MALDI-TOF tech-
nology has been adapted to bacterial identification and shows
promise as a potential replacement for existing techniques.
Rapid turnaround time and low cost make this an appealing
new option. VGS are emerging as important pathogens, espe-
cially in immunosuppressed individuals. As our understanding
of the disease manifestations and antimicrobial susceptibility
profiles associated with different VGS species continues to
expand, accurate species level identification of VGS may be-
come increasingly important.
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